<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3698">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391179</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00179783</org_study_id>
    <nct_id>NCT04391179</nct_id>
  </id_info>
  <brief_title>Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19</brief_title>
  <acronym>DICER</acronym>
  <official_title>Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most severe manifestations of COVID-19 include respiratory failure, coagulation problems,&#xD;
      and death. Inflammation and blood clotting are believed to play an important role in these&#xD;
      manifestations. Research in humans has shown that dipyridamole can reduce blood clotting.&#xD;
      This research study is being conducted to learn whether 14 days of treatment with&#xD;
      dipyridamole will reduce excessive blood clotting in COVID-19.&#xD;
&#xD;
      This study will enroll participants with confirmed coronavirus (SARS-CoV)-2 infection that&#xD;
      are admitted. Eligible participants will be randomized to receive dipyridamole or placebo for&#xD;
      14 days in the hospital. In addition, data will be collected from the medical record, and&#xD;
      there will also be blood draws during the hospitalization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 31, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in D-dimer</measure>
    <time_frame>baseline, up to approximately 28 days after last study drug administration</time_frame>
    <description>Increase in plasma D-dimer level compared with baseline at enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global composite rank score</measure>
    <time_frame>up to approximately 28 days after last study drug administration</time_frame>
    <description>Global composite rank score of death, mechanical ventilation, oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2), and World Health Organization (WHO) Ordinal score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>COVID</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Covid-19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Dipyridamole 100 Milligram(mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 milligrams (mg) by mouth (PO) four times a day (QID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given by mouth four times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipyridamole 100 Milligram(mg)</intervention_name>
    <description>Drug will be given for 14 days while in the hospital.</description>
    <arm_group_label>Dipyridamole 100 Milligram(mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo will be given for 14 days while in the hospital.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide informed consent prior to performing study procedures&#xD;
             unless they have a legally authorized representative (LAR)&#xD;
&#xD;
          -  Confirmed coronavirus (SARS-CoV-2) infection, enrolled ≤ 72 hours of hospital&#xD;
             admission or of COVID-19 confirmation&#xD;
&#xD;
          -  Currently hospitalized or anticipated hospitalization requiring supplemental oxygen ≤&#xD;
             6 liters per minute (LPM) by nasal cannula&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the opinion of at least two investigators, unlikely to survive for &gt;48 hours from&#xD;
             screening&#xD;
&#xD;
          -  Concurrent enrollment in a clinical trial with a cytokine inhibitor (targeting&#xD;
             interleukin-6 (IL-6), Interleukin-6 Receptor (IL-6R), IL-1, or Janus kinase). Use of&#xD;
             remdesivir is permitted.&#xD;
&#xD;
          -  Currently on invasive mechanical ventilation.&#xD;
&#xD;
          -  Hypotension defined as systolic blood pressure &lt; 90 mmHg on two sequential readings at&#xD;
             least 4 hours apart&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Concurrent dual antithrombotic therapy (aspirin or P2Y12 inhibitor plus&#xD;
             anticoagulation to treat deep venous thrombosis or pulmonary embolism (single&#xD;
             antiplatelet or anticoagulant agent at prophylaxis or therapeutic dose is permitted)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 5&#xD;
             times upper limit of normal, hemoglobin &lt; 8 grams per deciliter (g/dL), or platelets&#xD;
             &lt;50,000 per cubic millimeter (mm3)&#xD;
&#xD;
          -  History of recent major bleeding, defined in accordance with the criteria of the&#xD;
             International Society on Thrombosis and Hemostasis (ISTH).&#xD;
&#xD;
          -  Any physical examination findings and/or history of any illness that, in the opinion&#xD;
             of the study investigator, might confound the results of the study or pose an&#xD;
             additional risk to the patient by their participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Knight, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Shore UniversityHealth</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Jason Scott Knight</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Oxygen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

